CombiGene AB

Equities

COMBI

SE0016101935

Biotechnology & Medical Research

Delayed Nasdaq Stockholm Other stock markets 15:18:29 15/05/2024 BST			5-day change	1st Jan Change
3.25 ^SEK	-5.25%		-12.16%	+20.82%

03-13	CombiGene's Epilepsy Project CG01 Receives Patent in Two New Countries	CI
02-21	Orphazyme A/S acquired an additional unknown minority stake in CombiGene AB (OM:COMBI).	CI

CombiGene AB (publ) publishes annual report for 2023

April 26, 2024 at 02:00 pm

CombiGene announces that the annual report now is available on the Company´s homepage, www.combigene.com, and as an attachment to this press release.

About CombiGene

CombiGene’s vision is to provide patients affected by severe diseases with the prospect of a better life through gene therapy and other forms of advanced treatments.

Our business has three focus areas: sourcing of new and promising assets, development of these assets to proof of concept under our management and expertise, and outlicensing of the assets to a strategic partner for continued development and commercialization. Revenue is achieved through milestone payments and royalties.

The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB.

Please read Ingeneious, a newsletter from CombiGene which contains general news and information that is judged not to have a significant effect on the share price. Ingeneious and press releases are available at www.combigene.com

Latest news about CombiGene AB

CombiGene's Epilepsy Project CG01 Receives Patent in Two New Countries	03-13	CI
Orphazyme A/S acquired an additional unknown minority stake in CombiGene AB (OM:COMBI).	02-20	CI
CombiGene AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-16	CI
CombiGene AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-10	CI
CombiGene Taps Charles River Laboratories as Clinical Research Partner for Pain Project	11-01	MT
Combigene AB Chooses Charles River as Preclinical Toxicology Partner for COZY01 Pain Project	31/10/23	CI
CombiGene, Zyneyro to Start Clinical Studies of COZY01 Targeting Shingles	26/10/23	MT
CombiGene AB and Zyneyro Choose Initial Indication in the Cozy01 Pain Project	26/10/23	CI
Spark Therapeutics Terminates Collaboration Agreement for the Epilepsy Project CG01 with CombiGene AB	14/10/23	CI
CombiGene AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	25/08/23	CI
CombiGene CEO to Depart in September	30/06/23	MT
CombiGene AB Announces Chief Executive Officer Changes	30/06/23	CI
Combigene AB to Play an Integrate Part in the Development of National Infrastructure for ATMPs	24/05/23	CI
CombiGene AB Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
CombiGene AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	17/02/23	CI
Combigene Enters into Collaboration Agreement with Zyneyro for the Development of A Unique Concept for Effective Relief of Chronic Pain	09/01/23	CI
CombiGene AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	11/11/22	CI
Combigene AB Appoints Peter Ekolind as COO	27/09/22	CI
CombiGene AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	25/08/22	CI
CombiGene AB Reports Earnings Results for the First Quarter Ended March 31, 2022	12/05/22	CI
CombiGene AB Signs Agreement with A Potential Value of USD 328.5 Million with Spark Therapeutics	21/02/22	CI
CombiGene AB Reports Earnings Results for the Full Year Ended December 31, 2021	17/02/22	CI
CombiGene AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	17/02/22	CI
Combigene AB Announces GMP Production of CG01 Made Available for Preclinical Studies Planned to Enable First in Human Study	17/01/22	CI
Combigene and Spark Therapeutics Plan to Expand the Clinical Development Program to Include the U.S. as Well as Europe	16/12/21	CI

Chart CombiGene AB

Duration

Period

More charts

Company Profile

Combigene AB is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company specializes in development of treatments for neurological disorders. The Company's platform comprises the use of gene therapy vectors delivering a combination of transgenes encoding two or more of neuropeptide Y (NPY) receptors, galanin, galanin receptors, somatostatin, and somatostatin receptors, for the treatment of neurological and psychiatric diseases in humans and animals. The Company focuses on the development of an epilepsy treatment by means of an adeno-associated virus (AAV) vector carrying the transgenes for the neurotransmitter NPY and one of its receptors, the G protein-coupled receptor Y2.

Sector

Biotechnology & Medical Research

Calendar

17/05/2024 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
COMBIGENE AB	+20.82%	6.28M
VERTEX PHARMACEUTICALS INCORPORATED	+6.60%	111B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-12.57%	22.24B
ARGENX SE	-0.09%	21.25B
GENMAB A/S	-4.59%	18.97B
WUXI APPTEC CO., LTD.	-35.21%	18.52B
BEIGENE, LTD.	-10.62%	16.81B
SAREPTA THERAPEUTICS, INC.	+37.66%	12.54B
LEGEND BIOTECH CORPORATION	-25.37%	8.09B

Bio Therapeutic Drugs